Back to discover

Protein / target

Serotransferrin

Encoded byTFP02787Homo sapiensSwiss-Prot
UniProt: P02787Ensembl: ENSG00000091513HGNC: HGNC:11740NCBI Gene: 7018
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Transmembrane transporter binding

Strongest disease association

Alcohol drinking

Via encoding gene TF · Genetic evidence · score 0.74

Research activity

Emerging research

1 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.

View complete UniProt function annotation

Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation

Subcellular location

Secreted
Domains and Gene Ontology detail (40)

Domains & features

Transferrin-like 1Transferrin-like 2

Gene Ontology

  • Capical plasma membrane
  • Cbasal part of cell
  • Cbasal plasma membrane
  • Cblood microparticle
  • Ccell surface
  • Cclathrin-coated endocytic vesicle membrane
  • Cclathrin-coated pit
  • Ccytoplasmic vesicle
  • Cearly endosome
  • Cendocytic vesicle
  • Cendoplasmic reticulum lumen
  • Cendosome membrane

698 aa · 77 kDa

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TF

Gene-level evidence surfaced through the gene TFthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Alcohol drinking
0.75Moderately supported

Genetic evidence dominant · Open Targets 0.46

Urolithiasis
0.48Limited support

Genetic evidence dominant · Open Targets 0.29

Pre-Eclampsia
0.42Limited support

Genetic evidence dominant · Open Targets 0.24

Neurodegenerative Diseases
0.28Preliminary

Pathway evidence dominant · Open Targets 0.40 · no direct causal or clinical evidence

Prostatic Neoplasms
0.21Preliminary

Somatic mutation evidence dominant · Open Targets 0.13

View evidence synthesis (5)
Alcohol drinkingModerately supported
0.75
agreement 0.61–0.89
Genetic97%Literature3%

Open Targets aggregate 0.46 · 2 independent evidence families

UrolithiasisLimited support
0.48
agreement 0.34–0.62
Genetic98%Literature2%

Open Targets aggregate 0.29 · 2 independent evidence families

Pre-EclampsiaLimited support
0.42
agreement 0.28–0.56
Genetic88%Literature12%

Open Targets aggregate 0.24 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary
0.28
agreement 0.11–0.46
Pathway88%Literature12%

Open Targets aggregate 0.40 · 2 independent evidence families · no direct causal or clinical evidence

Prostatic NeoplasmsPreliminary
0.21
agreement 0.05–0.38
Somatic mutation52%Literature48%

Open Targets aggregate 0.13 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Alcohol drinking0.46
Neurodegenerative Diseases0.40
Urolithiasis0.29
Pre-Eclampsia0.24
Prostatic Neoplasms0.13
Familial prostate cancer0.13

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand and high-quality pocket) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Structure with LigandSM · High-Quality PocketAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

N/A, Breast CancerAOP-Wiki

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

1 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting.11 cites

Fontana F · PloS one · 2023

Recent

Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting.

Fontana F · PloS one · 2023

Europe PMC papers linked directly to this protein.